| ACTIVITY OF SUNITINIB MALATE IN NON-CLEAR CELL KIDNEY CANCER PATIENTS: A SINGLE INSTITUTION EXPERIENCE I Imarisio, C Paglino, C Ganini, C Canipari, C Porta ANNALS OF ONCOLOGY 21, 296-297, 2010 | | 2010 |
| Adoptive immunotherapy with autologous cytotoxic T lymphocytes (CTLs) pulsed ex vivo with patient-derived tumor cells in heavily pretreated, advanced renal cell carcinoma (aRCC … C Porta, D Montagna, C Paglino, S Secondino, C Bregant, C Ganini, ... Journal of Clinical Oncology 31 (15_suppl), 4575-4575, 2013 | | 2013 |
| Cancer predictive studies I Amelio, R Bertolo, P Bove, E Candi, M Chiocchi, C Cipriani, N Di Daniele, ... Biology direct 15 (1), 18, 2020 | 44 | 2020 |
| Cell Death: Apoptosis and Other Means to an End C Zampieri, C Ganini, G Melino CELL DEATH & DISEASE 11 (4), 2020 | | 2020 |
| Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients C Porta, C Paglino, I Imarisio, C Ganini, L Sacchi, S Quaglini, V Giunta, ... Oncology 84 (2), 115-122, 2012 | 95 | 2012 |
| Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification M Rizzo, A Caliò, M Brunelli, G Pezzicoli, C Ganini, G Martignoni, C Porta Cancer treatment reviews 116, 102558, 2023 | 14 | 2023 |
| From the Zeno's paradoxes to novel immunotherapeutic agents for kidney cancer: moving from an era of wrong premises and conclusions to a better comprehension of immunology C Porta, C Ganini, C Paglino Expert Opinion on Biological Therapy 13 (6), 813-815, 2013 | | 2013 |
| Gee J George S Gerullis H Giovannetti E J Gray, M Bailey, C Baxevanis, A Bilchik, B Brücher, R Caccialanza, ... | | |
| Global mapping of cancers: The Cancer Genome Atlas and beyond C Ganini, I Amelio, R Bertolo, P Bove, OC Buonomo, E Candi, C Cipriani, ... Molecular oncology 15 (11), 2823-2840, 2021 | 70 | 2021 |
| Il trattamento del carcinoma renale avanzato: un aggiornamento G Pezzicoli, C Ganini, RSG Vanessa, M Pirovano, L Cosmai, C Porta, ... | | |
| Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? C Porta, C Paglino, I Imarisio, C Ganini, P Pedrazzoli Journal of Cancer 2, 333, 2011 | 41 | 2011 |
| Lingual metastasis from renal cell carcinoma: a case report and literature review C Ganini, A Lasagna, E Ferraris, P Gatti, C Paglino, I Imarisio, P Morbini, ... Rare tumors 4 (3), 130-133, 2012 | 26 | 2012 |
| Liquid biopsies and cancer omics A Ivano, B Riccardo, B Pierluigi, OC Buonomo, C Eleonora, C Marcello, ... Cell Death Discovery 6 (1), 2020 | 1 | 2020 |
| Liquid biopsies and cancer omics I Amelio, R Bertolo, P Bove, OC Buonomo, E Candi, M Chiocchi, ... Cell Death Discovery 6 (1), 131, 2020 | 62 | 2020 |
| Liquid biopsies and cancer omics. Cell Death Discov. 2020; 6 (1): 131 I Amelio, R Bertolo, P Bove, O Buonomo, E Candi, M Chiocchi, C Cipriani, ... | 4 | |
| Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial C Porta, C Ganini, C Paglino Translational Andrology and Urology 1 (2), 120, 2012 | 1 | 2012 |
| No time to die: how kidney cancer evades cell death C Ganini, M Montanaro, M Scimeca, G Palmieri, L Anemona, L Concetti, ... International Journal of Molecular Sciences 23 (11), 6198, 2022 | 11 | 2022 |
| ONE-CARBON METABOLISM ENZYMES ACTIVITY MODULATION AS A POTENTIAL THERAPY IN KIDNEY CANCER C Ganini, L Concetti, A Cappello, G Melino, E Candi ANTICANCER RESEARCH 42 (10), 5138-5139, 2022 | | 2022 |
| Orai1 and transient receptor potential channels as novel molecular targets to impair tumor neovascularization in renal cell carcinoma and other malignancies F Moccia, S Dragoni, V Poletto, V Rosti, F Tanzi, C Ganini, C Porta Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2014 | 60 | 2014 |
| p63 in corneal and epidermal differentiation F Novelli, C Ganini, G Melino, C Nucci, Y Han, Y Shi, Y Wang, E Candi Biochemical and Biophysical Research Communications 610, 15-22, 2022 | 12 | 2022 |
